Anti-LPS enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder
Methods and compositions for treating conditions including liver dysfunction, e.g., associated with fatty liver; glucose intolerance; and others, by administering compositions comprising anti-LPS immunoglobulin enriched colostrum preparations.
1. A method of treating non-alcoholic steatohepatitis (NASH) in a subject who has one or more of:
an alanine aminotransferase (ALT) level above 50 IU/dL,
an aspartate aminotransferase (AST) level above 50 IU/dL,
an alkaline phosphatase (AP) of greater than 70 U/L, or
a γ-glutamyl transferase (GGT) of greater than 60 U/L,
the method comprising:
selecting a subject on the basis that they have NASH and one or more of:
an ALT level above 50 IU/dL,
an AST level above 50 IU/dL,
an AP of greater than 70 U/L, or
a GGT of greater than 60 U/L, and
orally administering to the subject who has NASH a therapeutically effective amount of a composition comprising an anti-LPS immunoglobulin-enriched colostrum preparation for at least 14 days.
2. The method of claim 1 , wherein the anti-LPS immunoglobulin preparation is prepared by immunizing a cow with LPS comprising O6, O8, O15, O25, O27, O63, O78, O114, O115, O128, O148, O153, and O159.
3. The method of claim 1 wherein the anti-LPS immunoglobulin preparation is administered at a dose of about 100 mg to about 2000 mg per day.
4. The method of claim 1 , wherein the anti-LPS immunoglobulin preparation is administered at a dose of about 1800 mg per day.
5. The method of claim 1 , wherein the subject has:
an ALT level above 50 IU/dL,
an AST level above 50 IU/dL,
an AP of greater than 70 U/L, and
a GGT of greater than 60 U/L,
the method comprising:
selecting a subject on the basis that they have NASH and:
an ALT level above 50 IU/dL,
an AST level above 50 IU/dL,
an AP of greater than 70 U/L, and
a GGT of greater than 60 U/L, and
orally administering to the subject who has NASH a therapeutically effective amount of a composition comprising an anti-LPS immunoglobulin-enriched colostrum preparation for at least 14 days.
6. The method of claim 1 , wherein the method comprises orally administering to the subject a therapeutically effective amount of a composition comprising an anti-LPS immunoglobulin-enriched colostrum preparation for at least 21 days.
7. The method of claim 1 , wherein the method comprises orally administering to the subject a therapeutically effective amount of a composition comprising an anti-LPS immunoglobulin-enriched colostrum preparation for at least 28 days.
8. The method of claim 1 , wherein the method comprises orally administering to the subject a therapeutically effective amount of a composition comprising an anti-LPS immunoglobulin-enriched colostrum preparation for at least 31 days.
9. The method of claim 1 , wherein the method comprises orally administering to the subject a therapeutically effective amount of a composition comprising an anti-LPS immunoglobulin-enriched colostrum preparation over several months.
10. The method of claim 1 , wherein the method comprises orally administering to the subject a therapeutically effective amount of a composition comprising an anti-LPS immunoglobulin-enriched colostrum preparation once or more monthly.